WHEL-C-073 · Moderate evidence · 6/10

relugolix combination therapy for endometriosis

Relugolix combination therapy is described as having an effect on endometriosis-associated pain versus placebo with reported two-year efficacy in women.

Origin · Existing drug · repurposing candidatePathway · 505(b)(2) · existing active ingredient, new indicationEvidence arm · Direct researchEvidence supports

How to read thisThe summary above and the proposed mechanism are generated by the model from the sources it ingested, and are written as the model’s reasoning rather than established fact. Any figure quoted from MATRIX is a model-derived association score, not a clinical measurement. How far the published record backs this pair is carried by the score’s own rigor dimension and traced to verbatim sources at the foot of the page.

Hypothesized mechanism

As a GnRH receptor antagonist combination therapy, relugolix likely suppresses ovarian estrogen production, reducing endometriosis-associated pain.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

How the score was reached, for this pair

The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 6 of 10 overall, a moderate reading, from a direct rated moderate in strength.

The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.

Direct research arm · anchors the headline6.0 / 10 · Moderate

Scored for women. Evidence generated in women (female population). (band F1, ×1.00).

Corroboration

Two claims appear to derive from a review/management article citing relugolix combination therapy trials, but no independent replication or large low-bias RCT is verified here. The evidence reflects single-source descriptions rather than multiple independent consistent studies.

1 / 2

Rigor

Claims describe placebo-controlled comparisons and two-year efficacy data suggestive of RCT-derived evidence, but the source is a management/review article and study design is not explicitly confirmed as RCT. Conservatively scored at observational/small trial level given limited detail.

1 / 2

Specificity

Both claims name relugolix combination therapy directly and endometriosis/endometriosis-associated pain explicitly. The drug and condition are both clearly identified.

2 / 2

Plausibility

Relugolix is a GnRH antagonist plausibly reducing endometriosis-associated pain via estrogen suppression, but the claims do not explicitly state or evidence this mechanism. Mechanism is plausible but not detailed in the quotes.

1 / 2

Consistency

The two claims both point toward a positive effect on endometriosis-associated pain (short-term vs placebo and two-year efficacy), but they are not independent studies allowing a directional consistency assessment. Treated as effectively single-source, scored neutral.

1 / 2

How the scoring rubric works, in general →

Layers not covered for this pair

Sex-specific pharmacokineticsNone on file

Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.

More on the sex-specific pharmacokinetics layer and its sources →

Cycle-phase dependenceNone on file

Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.

More on the cycle-phase layer and its sources →

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

1Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain PubMed · PMID 39159261 ↗
2Once daily oral relugolix combination therapy vs. placebo in patients with endometriosis-associated pain PubMed · PMID 39159261 ↗
3Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain PubMed · PMID 39159261 ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.

The primary sources and pipelines this evidence is drawn from →

← Back to the full index